Antidepressants are commonly employed for the treatment of major depressive disorders and other psychiatric conditions. We investigated the relatively acute cytotoxic effects of three commonly prescribed antidepressants: fluoxetine, sertraline, and clomipramine on rat primary blood brain barrier endothelial cells over a concentration range of 0.1-100 μM. At therapeutic concentrations (0.1 μM) no significant cytotoxicity was observed after 4, 24, or 48 h. At high therapeutic to overdose concentrations (1-100 μM), antidepressants reduced cell viability in proportion to their concentration and exposure duration. At 1 μM, antidepressants significantly reduced mitochondrial membrane potential. At drug concentrations producing~50% inhibition of cell viability, all drugs significantly reduced cellular oxygen consumption rates, activities of mitochondrial complexes I and III, and triggered a significant increase of lactate production. Fluoxetine (6.5 μM) and clomipramine (5.5 μM) also significantly lowered transcellular transport of albumin. The mechanism of cellular cytotoxicity was evaluated and at high concentrations all drugs significantly increased the production of reactive oxygen species, and significantly increased the activity of the pro-apoptotic caspases-3, 8, and 9. Comet assays revealed that all drugs were genotoxic. Pre-incubation of cells with glutathione significantly ameliorated antidepressant-induced cytotoxicity, indicating the potential benefit of treatment of overdosed patients with antioxidants.
Introduction
Major depressive disorder (MDD) is a multifactorial disease affecting an estimated 350 million people worldwide and across all ages (WHO, 2016) . Depression is the leading cause of disability and a major contribution to the global burden of disease (Smith, 2014; WHO, 2016) . Antidepressants are first-line therapeutic drugs used to treat MDDs, and other conditions including dysthymia, anxiety disorders, obsessive-compulsive disorder (OCD), and also to combat neuropathic pain and migraines. Antidepressants can be loosely categorised into tri cyclic antidepressants (TCAs); cyclic antidepressants; mixed action agents; selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine reuptake inhibitors; monoamine oxidase inhibitors; and alternative (non-traditional) antidepressants (Ciraulo et al., 2004) .
Many factors influence antidepressant drug selection including the potential of pharmaco-toxicity. Patient trialling of an antidepressant drug may require an adequate dose of drug for several weeks to prove efficacious, and pharmacotherapy then continued for~6-12 months or indeed indefinitely for recurrently depressed patients. This raises concerns of both acute and chronic drug-induced cytotoxicity.
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Over the last two decades there has been upward trend in prescribing of antidepressants in the USA and UK (Mojtabai and Olfson, 2014; Mars et al., 2017) ; which for the UK was driven by an increase in prescribing SSRIs such as Fluoxetine (FLX) and Sertraline (SER). FLX is now the first choice antidepressant used to treat children and adolescents as a monotherapy of unipolar depression, and is approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) (Masi et al., 2010; Taurines et al., 2011) . SSRIs are thought to relieve depression symptoms by a number of mechanisms that include increasing serotonin (5-hydroxytryptamine) levels in the brain. SSRIs inhibit serotonin reuptake transporters at presynaptic terminals and thereby sustain levels of serotonergic neurotransmitter levels at post-synaptic clefts (Benfield et al., 1986; Murdoch and McTavish, 1992; MacQueen et al., 2001; Ciraulo et al., 2004; Perez-Caballero et al., 2014) .
In contrast to SSRIs, the number of prescriptions of TCAs in the UK, such as Clomipramine (CLM), has remained stable over the same time course (Mars et al., 2017) . TCAs mainly exert their effects via inhibition of presynaptic neural reuptake of serotonin and nor-epinephrine (McTavish and Benfield, 1990; Ciraulo et al., 2004; Gillman, 2007) . Although prescribing CLM is associated with a greater benefit compared to placebo than that seen for SSRIs for treating paediatric OCD, it is not recommended for first-line use because of its adverse effects and limited tolerability (Varigonda et al., 2016) .
To exert their cellular effects, antidepressants need to cross the blood brain barrier (BBB). The BBB is comprised of endothelial cells that are associated together by tight and adherens junctions. This interlinking of endothelial cells with little fenestration limits the ability of molecules to cross them from the blood to enter brain tissue. The basement membrane of the endothelial cells (and resident pericytes) is also in close association with foot processes of brain glial cells such as astrocytes. Hence the BBB provides a protective cell layer that separates the CNS from circulatory blood and is able to regulate the uptake of endogenous molecules and xenobiotics into the brain (Schinkel, 1999; Abbott et al., 2010; O'Brien et al., 2012) . Certain small lipophilic molecules (< 400 Da in size) are able to cross the BBB by passive diffusion, whereas other (larger) molecules and certain drugs including antidepressants, may be uni-directionally transported from the brain across the BBB to the blood driven by the consumption of ATP (Schinkel and Jonker, 2003; Horstmann and Binder, 2009; O'Brien et al., 2012) . These luminal membrane energy-dependent efflux pumps include proteins of the multidrug resistance-associated (MDR) gene family such as P-glycoprotein (P-gp), and act to provide resistance to drug toxicity (Regina et al., 1998; Schinkel, 1999; Schinkel and Jonker, 2003; Horstmann and Binder, 2009; Abbott et al., 2010; O'Brien et al., 2012) .
A number of established protocols exist for production of BBB cells that use isolated monocultures of endothelial cells of primary or tumorigenic origin, or mixed co-cultures that include glial cells such as astrocytes (Abbott et al., 1992; Perrière et al., 2005; Roux and Couraud, 2005; Weksler et al., 2005) . The ability to culture cell lines continually provides convenience and initial reproducibility, but ultimately progressive genetic and phenotypic cell changes may arise and lead to dedifferentiation and selection of rapidly proliferating clones. Furthermore, lab-specific culturing conditions promote culture outgrowth. Human primary cells provide physiologically relevant cells, but ethical clearance and cost may be prohibitive to use. By contrast, although there are limitations associated with species specific responses, laboratory rats provide a useful source of primary cells to model drug effects on BBB endothelial cells.
Thus the ability to isolate and culture primary rat endothelial cells of the BBB provides an in vitro model able to evaluate local cytotoxicity that could impact upon BBB integrity and functionality. The objective of this study was to assess the cytotoxicity of two of the widely prescribed antidepressants from the SSRIs class, FLX and SER, and CLM from the TCAs class, to rat cerebral microvascular endothelial cells (rCMEC), and examine the molecular mechanism of any drug-induced cytotoxicity. (N-methyl-3-phenyl-3-[4-(trifluoromethyl) 
Materials and methods

Chemicals and reagents
Fluoxetine
Animals
Male Albino rats (~250 g body weight) were used for this study. All experiments were approved by the Mansoura Faculty of Medicine Ethical Committee. Rats were sacrificed under sodium pentobarbital anaesthesia.
Isolation and characterisation of rat cerebral microvascular endothelial cells (rCMECs).
Isolation of rCMECs was based upon published methods (Abbott et al., 1992; Regina et al., 1998; Perrière et al., 2005; Weksler et al., 2005; Calabria et al., 2006; Nakagawa et al., 2009; Liu et al., 2014) . After isolation, cells were purified using a 33% continuous Percoll gradient. Cells were washed and then plated on 35 mm collagen IV/fibronectin-coated plates (0.1 mg/ml). Isolated cells were maintained in Endothelial Cell Growth Medium (Sigma 211-500) supplemented with 4 μg/ml puromycin and 100 mg/ml heparin and maintained in 5% CO 2 at 37°C. After 3 days, puromycin was removed from the media (Liu et al., 2014) . Primary BBB endothelial cells were of the typical elongated spindle-like morphology (Abbott et al., 1992) , and were essentially homogeneous when visualized by light microscopy ( Supplementary Fig.  S1 ), consistent with the~99% purity estimates detailed by others Calabria et al., 2006) . Under these culturing conditions, BBB endothelial cells display improved barrier properties in part mediated by increased expression of tight junction proteins (Calabria et al., 2006) . Further purity confirmation was established via expression of the BBB endothelial cell transport proteins P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP), and the puromycin-induced expression of the tight junction proteins Zonula occludens-1 (ZO-1) and Occludin by Western blotting. (Regina et al., 1998; Schinkel, 1999; Abbott et al., 1992; Schinkel and Jonker, 2003; Perrière et al., 2005; Weksler et al., 2005; Calabria et al., 2006; Horstmann and Binder, 2009; O'Brien et al., 2012) .
Cell homogenates were resolved using a 4% acrylamide/bisacrylamide gel, proteins transferred to a nitrocellulose membrane, and then membranes washed and incubated in blocking buffer according to previous publications (Erdozain et al., 2014; Carter et al., 2015) . Blocked membranes were incubated with primary antibodies: anti-P-gp monoclonal antibody (C219, Signet Laboratories, Dedham, MA, USA) at 1:200 dilution, anti-BCRP (Bxp-53, Enzo Life Sciences, Farmingdale, NY, USA) at 1:5000, anti-ZO-1 rabbit polyclonal (Invitrogen) at 1:1000, Elmorsy et al. Toxicology in Vitro xxx (2017) 
Cell viability assays
Cells were seeded at 1 × 10 4 cells per well in 96-well plates and grown until confluent. Cells were then incubated for 4, 24, and 48 h in the presence of the antidepressant drugs at concentrations of 0.1, 1, 10 and 100 μM. To evaluate cell cytotoxicity, cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) according to a previous publication (Elmorsy et al., 2014) . MTT absorbance values were expressed as a percentage of vehicle controls (defined as 100%). Each drug concentration was tested in 3 separate experiments and each experiment performed in triplicate.
Alamar Blue (AB) (InVitrogen) dye binding fluorescence was also used as a measure of cell viability (O'Brien et al., 2000; Elmorsy and Smith, 2015) . After incubation with drugs, 10 μL of AB reagent was added per well, plates incubated for 4 h, and then the absorption read at 590 nm using a Dyne MRX microplate reader (Dyne Technologies, Chantilly, USA). Viability was expressed as a percentage of DMSO vehicle control readings (set at 100%). Each drug concentration was tested in 3 separate experiments and each experiment performed in triplicate.
For assays of trypan blue exclusion, cells were cultured in 24-well plates, grown until confluent and treated with antidepressants at the same concentrations used for MTT assays. Twenty-four hours post-treatment, both the attached and floating cells were harvested, resuspended in 1 ml phosphate buffered saline, and then 100 μl 0.4% trypan blue added. Cell viability as trypan blue exclusion was measured using a haemocytometer, with results expressed as percentage viability relative to control treated cells. Experiments were repeated at least 3 times for each drug treatment and each experiment was performed in triplicate.
Intracellular ATP levels were quantified using an ATP assay kit (Abcam, Cambridge, MA, USA) according to the manufacturer's guidelines, as detailed in Elmorsy et al. (2016) . Briefly, cells were seeded at 1 × 10 4 cells per well in 96-well plates, and grown until confluent. Cells were then treated with antidepressants for 24 h, lysed, and measurements taken using a luminometer 'TopCount' (Perkin Elmer, Uberlingen, Germany). Readings of blank wells were subtracted from sample readings. ATP levels were expressed relative to vehicle control readings. Experiments were repeated at least 3 times for each drug treatment and each experiment was performed in triplicate.
Mitochondrial measurements
Determination of mitochondrial membrane potential (MMP), and mitochondrial complex I and complex III activity assays were performed according to Elmorsy et al. (2016) . Cells were seeded in 24 well plates at 3 × 10 4 cells/well and grown to confluence. Cells were then incubated with drugs for 24 h at 0.1, 1, 10, or 100 μM for MMP assays, and at a concentration producing 50% inhibition (IC 50 ) by AB assay (23, 38, and 30 μM for FLX, SER, and CLM, respectively), for mitochondrial complex I or complex III assays. Additionally to establish a dose and effect relationship, mitochondrial complex I and complex III assays were also performed after exposure of cells to drugs at 10 μM for 24 h. Fluorescence measurements were taken using excitation/emission filters of 490 ⁄ 451 nm, respectively. For MMP measurements (Δψ mit ), carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP), a protonophoric uncoupler of oxidative phosphorylation, was used at 10 μM as a positive control. MMP measurements were also recorded using Rhodamine-123 (Rh-123) (Sigma, R8004) dye binding. In this assay a reduction of the integrity of the MMP triggers a redistribution of Rh-123 and is associated with an increase of fluorescence (Emaus et al., 1986; Baracca et al., 2003; Daunt et al., 2005) . After drug treatments, cells were harvested, counted, and incubated in a modified Hanks' solution (5.6 mM KCl, 138 mM NaCl, 4.2 mM NaHCO 3 , 1.2 mM NaH 2 PO 4 , 2.6 mM CaCl 2 , 1.2 mM MgCl 2 , 10 mM HEPES, pH 7.4) containing Rh-123 (50 μg/ml) at 37°C for 3 min. FCCP was added to confirm the functional integrity of the mitochondrial membranes. Fluorescence measurements were undertaken using an excitation of 480 nm and emission of 530 nm. Fluorescence was normalised to the number of cells present. Experiments were undertaken 5-6 times with each drug at each concentration, with each experiment performed in triplicate.
Oxygen consumption rates
Oxygen consumption rates (OCRs) were assessed polarographically using Clark oxygen electrodes (Rank Brothers, Saudi Arabia). Cells were treated with drugs (AB IC 50 concentrations and at 10 μM) or vehicle control for 24 h, and then harvested into modified Hanks' solution containing 0.1% (w/v) BSA. Basal OCRs were recorded and after 10 min sodium azide was added (6 mM final concentration) to inhibit further oxygen consumption. OCRs were determined as the change of O 2 tension over a 5 min time-course. For the effect of sodium azide, measurements were taken 60 s after addition. OCRs were normalised to the number of cells present (Daunt et al., 2005; Elmorsy and Smith, 2015) . Experiments were undertaken 5-6 times with each drug at each concentration, with each experiment performed in triplicate.
Lactate production
Cells were seeded in 24-well plates (5 × 10 4 cells per well) and grown until confluent. Cells were then treated with antidepressants at their AB IC 50 concentrations and at 10 μM for 24 h. Lactate was measured in the supernatant using a lactate assay kit (Biovision, Mountain View, CA, USA) according to the manufacturer's instructions. Lactate production were normalised to the number of cells present and expressed as a percentage of lactate produced by vehicle control treated cells. Experiments were performed with three replicates of each treatment, and repeated at least three times.
Transcellular albumin transport
Cells were grown to confluence in 24-well inserts (area 0.6 cm 2 ; 0.4 μM, Millicell, Millipore Corporation). Cells were treated with drugs for 48 h at concentrations of 6.5, 6.5, and 5.5 μM for FLX, SER, and CLM, respectively (concentrations of half of their respective AB assay IC 50 s). Control assays were performed with wells incubated with DMSO vehicle and media only. To assess transcellular permeability, Evans blue (0.05 mg/ml) labelled albumin (4%) was added to media within the inserts. After 3 h, the infranatent media within the main well was collected and the passage of labelled albumin across the cell monolayer determined by measuring absorbance at 620 nm (Elmorsy et al., 2014) . Experiments were performed with three replicates of each treatment, and repeated at least three times. Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx 
Reactive oxygen species (ROS) production
Twenty-four hours post-drug treatments, a 3,7-dichlorodihydrofluorescein diacetate (DCFDA) assay was used to detect the presence of ROS. For each drug, both MTT IC 50 and 10 μM concentrations were used. The assay was performed according to a previous publication (Elmorsy et al., 2014) . Cell treatment with Antimycin A (10 μM for 30 min) was used as a positive control, while non-stained cells were used as a blank. Cells were washed with PBS and then measured for fluorescence with 485 nm excitation and 535 nm emission wavelengths. The non-stained cell blank values were subtracted from vehicle control (ethanol) and drug assay values. Experiments were performed with three replicates of each treatment, and repeated at least three times.
Measurements of apoptosis
Activity of Caspases 3, 8, and 9 were measured 4 h after drug treatments, with drugs applied at their MTT IC 50 concentrations. Caspase activities were determined using BD ApoAlert caspase fluorescent assay kits (Clontech Laboratories, Palo Alto, CA, USA) according to the manufacturer's protocols. Experiments were performed with three replicates of each treatment, and repeated at least three times.
Measurements of DNA damage
Single and double-stranded DNA breaks were detected by an alkaline Comet assay (Lee and Steinert, 2003) . Cells were treated with the drugs at their MTT IC 50 concentrations and also at 10 μM for 24 h. Cells were harvested in ice-cold PBS. Comet assays were performed according to published procedures (Singh et al., 1988; De Méo et al., 1991) . After cell lysis, samples were electrophoresed for 30 min at 300 mA and stained with propidium iodide (1 mg/ml). Cells were imaged by fluorescent microscopy at 546 nm excitation and 640 nm emission wavelengths. Images were analysed by Comet score IV software (Perspective Instruments, UK). Assays were performed 4-5 times for each drug concentration.
Cell incubations with glutathione (GSH)
Cells were incubated with 10 μM of GSH or vehicle controls for 48 h prior to drug treatments. Cells were then washed and incubated with antidepressants for 24 h at their MTT IC 50 concentrations and also at 10 μM. MTT cell cytotoxicity assays and Comet assays were then performed. All experiments were performed at least three times, with each treatment assayed in triplicate.
Statistical analysis
Statistical analysis was performed using PRISM 5 (GraphPad Software Inc., San Diego, CA, USA) with significance defined as p < 0.05. For comparisons of three or more groups, a one way analysis of variance (ANOVA) test was performed with Dunnett's multiple comparisons post-test. For two groups a Student's t-test was used. Data points in graphs or histograms in Figures represent means ± SDs. IC 50 values were calculated using a nonlinear regression analysis (log (inhibition) versus response (variable slope) using a least squares algorithm using Prism. Significance is indicated in Figures as *** for p < 0.001, ** for p < 0.01, and * for p < 0.05.
Results
Antidepressants are cytotoxic to rCMECs
rCMECs were isolated according to published methods (Section 2.2), cultured in the presence of puromycin to facilitate elimination of contaminating cells, and then characterised by the expression of BBB endothelial transport proteins, P-gp and BCRP, and puromycin-induced expression of tight junction proteins ZO-1 and Occludin ( Supplementary  Fig. S1 ), prior to experimentation.
The antidepressants FLX, SER, and CLM were assessed for cytotoxicity to rCMECs using MTT assays (Fig. 1A) , Alamar Blue assays (Fig.  1B) , and depletion of cellular ATP levels (Fig. 1C) . At a concentration of 0.1 μM no significant reductions of cell viability or cellular ATP levels were observed (Fig. 1A-C) . However, cell cytotoxicity (decreased cell viability) correlated with both higher drug concentrations (1-100 μM) and with increased exposure duration (Supplementary Table 1 ). All three antidepressants displayed similar toxicological profiles but SER was the least potent drug (highest IC 50 concentration) after a 24 hour drug exposure (Fig. 1A-C and Table 2 ). Twenty-four hour antidepressant-induced cytotoxic effects were also independently validated via a decreased ability of treated rCMECs to exclude trypan blue dye relative to control cells ( Supplementary Fig. S2 ).
Antidepressants reduce cellular bioenergetics
Antidepressants depleted cellular ATP levels in a dose-dependent fashion (Fig. 1C) . Similarly, a dose-dependent significant reduction of mitochondrial membrane potential (MMP) was observed using direct Mitotracker dye binding ( Fig. 2A, upper panel) . As an alternative measure of MMP, Rhodamine-123 dye binding was used and demonstrated a significantly increased fluorescence (consistent with reduced MMP) after antidepressant incubation at IC 50 concentrations, and for FLX a significant increase was also observed at 10 μM ( Fig. 2A , lower panels). When applied at their IC 50 concentrations, FLX, SER, and CLM all significantly inhibited mitochondrial complex I (MC-I) activity by 27, 13, and 19%, respectively (p = 0.0037). FLX, the most potent inhibitory drug was also able to significantly suppress MC-I activity at 10 μM (Fig. 2B) . Mitochondrial complex III (MC-III) was significantly inhibited (20-25%) by all three drugs at their IC 50 concentrations (p = 0.0006), and also significantly reduced 13 and 15% at 10 μM concentrations of FLX or CLM, respectively (Fig. 2C) . FLX, SER, and CLM significantly reduced cellular oxygen consumption rates (p = 0.0006) by 64, 31, and 45%, respectively, at their IC 50 concentrations, but not at 10 μM (Fig.  2D) . The production of cellular lactate was also significantly increased by all drugs at their IC 50 concentrations (33-44%, p = 0.0018) but not after cell dosing at 10 μM (Fig. 2E) .
Antidepressants reduce transcellular transport of albumin
To assess a functional deficit of BBB endothelial cell activity, the ability of rCMECs to transport EB-labelled albumin was quantified. Antidepressants were administered at high therapeutic concentrations of 6.5, 6.5, and 5.5 μM for FLX, SER, and CLM, respectively. Significantly reduced transcellular albumin transport was observed after incubation with FLX (21% reduction) or CLM (17% reduction) (p = 0.0059) but not SER (Fig. 3) .
Antidepressant cytotoxicity correlated with increased ROS production
To provide an insight into the molecular mechanism that drives cellular cytotoxicity, a DCFDA assay was performed to assess levels of Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx ROS. FLX, SER, and CLM all significantly increased the production of ROS at their~IC 50 concentrations (~17, 10, and 12-fold change, respectively, (p = 0.0016)), with the most significant increase generated after cell treatment with FLX (Fig. 4, left panel) . At 10 μM, FLX also induced~3-fold significant increase of ROS production (p = 0.0235) (Fig. 4, right panel) .
Antidepressant cytotoxicity is mediated via increased apoptosis and DNA damage
The pro-apoptotic cellular caspases 3, 8, and 9 were all significantly activated (1.5-2.3-fold) by each of the antidepressants (p < 0.0001, p < 0.0001, and p = 0.0084, respectively) ( Fig. 5A-C) . Genotoxic effects were also assessed via quantification of Tail DNA (TD) and Tail moment (TM). At their IC 50 concentrations FLX, SER, and CLM all significantly increased TD percentage (~3-3.5-fold, p = 0.001) (Fig. 6A,  upper panel) , and FLX also significantly increased TM percentage~2.5 fold (p = 0.0011) (Fig. 6B, upper panel) . At 10 μM, FLX was also still able to significantly increase TD percentage (~2.2-fold, p = 0.024) (Fig. 6A, lower panel) , but no significant changes to TM percentage were observed after dosing cells with antidepressants at 10 μM (Fig. 6B,  lower panel) .
Cytotoxic protection by glutathione
Cells pre-incubated with the antioxidant GSH for 48 h prior to antidepressant drug treatment at IC 50 concentrations displayed significantly reduced levels of cytotoxicity (p = 0.027, p = 0.005, and p = 0.028 for FLX, SER, and CLM, respectively) (Fig. 7, upper panel) . Cell cytotoxicity in response to drug concentrations of 10 μM was also countered after glutathione pre-incubations but these changes did not reach significance (Fig. 7, lower panel) .
Discussion
Cytotoxicity of antidepressant drugs
Our aim was to evaluate the potential cytotoxicity of antidepressants to endothelial cells of the BBB. We scrutinised three antidepressant drugs (FLX, SER, and CLM) that are widely prescribed to treat a range of psychiatric problems including MDD. We employed a combination of assays to provide independent and overlapping means to establish cellular cytotoxicity: MTT and AB dye binding assays that display overlapping sensitivities for measuring cellular metabolic (reducing) activity (O'Brien et al., 2000) ; ATP levels as a measure of active cellular functionality; and the ability to exclude trypan blue to establish the presence of an intact cell membrane with associated cell viability.
To provide clinical relevance to our in vitro study we assessed cytotoxicity across a broad concentration range. Our study was designed to cover therapeutic, hyper-therapeutic, and also overdose concentrations, and enabled us to examine the molecular mechanisms that drive drug-induced cytotoxicity within a 24 h time-frame, and without our results being compounded by extensive cellular proliferation. Patients are typically prescribed FLX at a dosage of between 20 and 80 mg per day (Benfield et al., 1986; Ciraulo et al., 2004; Gartlehner et al., 2011) . Since FLX has an elimination half-life of several days, steady-state plasma levels of 0.2-0.3 mg/L (~0.6-1 μM) have been recorded after~2-4 weeks of 60 mg/day (Benfield et al., 1986) . SER is administered at a typical 50-200 mg daily dosing (Gartlehner et al., 2011) , with peak plasma concentrations of 20-55 μg/L (0.07-0.2 μM) observed 4-8 h after dosing of 100 mg SER (Murdoch and McTavish, 1992) . There is a positive correlation between oral dose of SER and drug plasma levels ranging from~14-113 ng/ml (up to~0.4 μM), with plasma levels of 25-50 ng/ml (~0.1-0.16 μM) adequate for clin E. Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx (E) Lactate production in cell supernatants was determined after a 24 h incubation with antidepressants at their IC 50 concentrations or at 10 μM. 24 h IC 50 concentrations were used for all experiments. Histograms are displayed relative to vehicle control values of 100%, with significant changes from controls marked with asterisks. For significance: *** for p < 0.001, ** for p < 0.01, and * for p < 0.05. Fig. 3 . Antidepressants effects upon transcellular albumin transport.rCMECs were incubated with antidepressants at concentrations of 6.5, 6.5, and 5.5 μM for FLX, SER, and CLM, respectively, for 48 h. After 3 h the passage of Evans blue-labelled albumin across the cell monolayer was determined. Transcellular albumin transport values significantly different from controls (100%) are marked with asterisks. For significance, ** for p < 0.01, and * for p < 0.05. ical management (Mauri et al., 2003) . CLM is usually administered at a dose range of 50-250 mg/day, with steady-state plasma concentrations of~100-300 μg/L (~0.3-1 μM) reported after 7-14 days of 100-200 mg/day (Stern et al., 1980; McTavish and Benfield, 1990) .
Patients with MDD often experience suicidal ideation, with a high risk of suicide particularly at the initial phase of treatment prior to experiencing therapeutic benefit. Hence overdosing with anti-depressants may be a chosen form of suicide (Buckley and McManus, 2002) . SSRIs have a high therapeutic index and moderate overdoses may still be asymptomatic and without serious sequelae, whereas adverse effects may be evident at high overdose levels (Barbey and Roose, 1998) . Recommendations suggest emergency department referral for patients that have taken greater than five times their therapeutic dose (Nelson et al., 2007) . Patient fatality may occur at overdose, particularly when co-ingested with other substances such as alcohol (Barbey and Roose, 1998) . Details of overdose concentrations are compounded by factors including limited reporting of patient age, time of blood sampling post-mortem, and possible co-ingested drugs. Nevertheless, a number of reports of plasma concentrations of overdosed patients exist: for FLX concentrations of~15-19 μM (Kincaid et al., 1990; Barbey and Roose, 1998; Schulz et al., 2012) ; SER from~5-10 μM (Schulz et al., 2012) ; and CLM from 3-6 μM (Schulz et al., 2012) .
Our study demonstrated that antidepressants are cytotoxic to rCMEC at hyper-therapeutic and overdose concentrations (1-100 μM) after 24-48 h exposures. Accumulating experimental evidence similarly supports cytotoxic and anti-proliferative effects of these antidepressants on cells grown in culture, animal models, and human studies of drug-induced liver injury (Hansson et al., 1997; Davies and Kluwe, 1998; Carvajal García-Pando et al., 2002; Thibaut and Porte, 2008; Krishnan et al., 2008; Li et al., 2012; Chen et al., 2014; Voican et al., 2016) . Our studies suggest that 24 h post-treatment SER is the least cytotoxic to BBB cells of the antidepressants investigated and displayed Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx Fig. 4 . Production of reactive oxygen species as a response to cell treatment with antidepressants.rCMECs were incubated with antidepressant drugs at their 24 h MTT IC 50 concentrations or at 10 μM for 24 h and the levels of reactive oxygen species determined using a DCFDA assay. Histograms depict mean values ± SD. Significant changes from controls are marked with asterisks. For significance: ** for p < 0.01, and * for p < 0.05. the highest IC 50 values, but by 48 h all three antidepressants were of similar toxicity (Table 1) .
Antidepressant-induced inhibition of cellular bioenergetics and induction of apoptosis
We have demonstrated that at hyper-therapeutic concentrations antidepressants are able to inhibit mitochondrial function ( Fig. 2A-C) and deplete cellular ATP levels (Fig. 1C) . The proton ionophore FCCP was used as a positive control for disruption of the MMP. FCCP, a weak liposoluble acid, is able to diffuse across the IMM and dissipate the proton gradient to reduce the MMP (Fig. 2A, upper panel) . By contrast, at 10 μM the antidepressants FLX, SER, and CLM were only weak inhibitors of MC-I or MC-III, hence amelioration of MMP was not as extensive as FCCP.
The antidepressant-induced reduction of mitochondrial function and cellular bioenergetics was evidenced by reduced cellular oxygen consumption rates (Fig. 2D) , and increased anaerobic metabolism and lactate production (Fig. 2E) . Additionally, the energy (ATP) requiring adsorptive-mediated transcytosis of albumin across rCMECs (Smith and Borchardt, 1989; Poduslo et al., 1994; Hervé et al., 2008; Abbott et al., 2010) was also impaired (Fig. 3) .
The inhibition of mitochondrial function and induction of apoptosis may well be one of the common mechanisms of drug-induced cytotoxicity including that triggered by antidepressants (Xia et al., 1998; Levkovitz et al., 2005; Lee et al., 2009; Li et al., 2012; Hynes et al., 2013; Mun et al., 2013; Chen et al., 2014; Elmorsy et al., 2014 Elmorsy et al., , 2016 . Induced apoptosis may proceed via a number of extrinsic and/ or intrinsic pathways that trigger activation of a cascade of caspases that culminate with activation of the 'executioner' caspase-3 (Elmore, 2007) . All three antidepressants activated caspases-3, 8 and 9, indicative of triggering both extrinsic and intrinsic apoptotic pathways.
Antidepressant-induced redox stress and DNA damage
The antidepressants induced cellular redox stress via an increased production of reactive oxygen species (ROS). ROS induction was in the order FLX > CLM > SER, a pattern we also observed for 24 h cytotoxicity assays. ROS are produced under normal physiological conditions but also under pathological conditions such as from damage to MC-I activity (Valsecchi et al., 2010) . Primary targets of drug-induced ROS damage are membrane lipids (producing lipid peroxidation), proteins, and DNA (Deavall et al., 2012) . We observed increased production of thiobarbituric acid-reactive products as markers of lipid peroxidation in response to antidepressant treatment of rCMECs (our unpublished results). Mitochondria are also susceptible to ROS damage, contributing to a disruption of the MMP, and triggering the release of cytochrome c for induction of apoptosis (Ott et al., 2007) .
The genotoxicity we observed after incubation with antidepressants may also have been a consequence of ROS production, and/or from the generation of other toxic cellular metabolites including antidepressant radicals. In support of our results, other independent studies have reported the induction of oxidative stress and genotoxicity after antidepressant drug treatment (Post et al., 2000; Slamon et al., 2001; Brambilla et al., 2009; Draz et al., 2009; Korobkova et al., 2012; Battal et al., 2014) . To further validate the importance of oxidative stress in antidepressant-induced cytotoxicity, pre-incubation of cells with a relatively high concentration (10 μM) of the antioxidant GSH was able to significantly reduce their cytotoxicity. Additionally, GSH pre-incubation was able to protect cells from antidepressant-induced DNA breakages at antidepressant IC 50 concentrations (our unpublished results).
Safety concerns with the prescription of antidepressant drugs
Our studies demonstrate that 24 or 48 h after exposure to a high therapeutic dose of 1 μM FLX, SER, or CLM, BBB cells experience diminished cellular bioenergetics and significant cytotoxicity. Although other studies have reported cytotoxic effects of antidepressant drugs, our study is the first to focus specifically on antidepressant-induced toxicity to rat primary microvascular endothelial cells of the BBB. Ghosh et al. (2015) reported that human brain microvascular cells (HBMECs) displayed mild toxicity to 5 μM SER, although the period of incubation was for 15 min and the precise level of toxicity not quantified (Ghosh et al., 2015) .
Our study is not without limitations; there is the potential for differential cytotoxicity to antidepressants between rat and human cells, and monocultured cells lack the influence of glia, restricting direct extrapolation to the human multi-cellular BBB. However, in vitro models (such as ours) that assess cytotoxicity and mitochondrial dysfunction have predictive benefit for human cytotoxicity. Indeed an assessment of mitochondrial dysfunction when combined with cellular OCR measurements has useful predictivity for high-throughput drug toxicity screening (Hynes et al., 2013) .
Our mechanistic studies suggest that cytotoxicity was associated with ROS production, genotoxicity and activation of apoptosis. The ability of glutathione to counter antidepressant-induced cytotoxicity indicates the potential therapeutic benefit of co-administration of antioxidants with antidepressants for patients receiving high dosage or indeed to limit cellular damage experienced by patients that are clinically overdosed.
U N C O R R E C T E D P R O O F
E. Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx Fig. 5 . Caspase activation as a response to cell treatment with antidepressants.rCMECs were incubated with antidepressant drugs at their 24 h MTT IC 50 concentrations for 4 h and then activity of caspase-3 (A), caspase-8 (B), and caspase-9 (C) determined relative to vehicle controls. Histograms depict mean values ± SD. Significant changes from controls are marked with asterisks. For significance: *** for p < 0.001, ** for p < 0.01, and * for p < 0.05.
E. Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx Fig. 6 . DNA damage as a response to cell treatment with antidepressants.rCMECs were incubated with antidepressant drugs at their 24 h IC 50 concentrations (6A, 6B, upper panels) or at 10 μM (6A, 6B, lower panels) for 24 h and the production of DNA breaks determined by alkaline Comet assays. The Tail parameters: Tail DNA (TD) and Tail moment (TM) were quantified in antidepressant treated cells and vehicle controls. Histograms depict mean values ± SD. Significant changes from controls are marked with asterisks. For significance: ** for p < 0.01, and * for p < 0.05. Fig. 7 . The effect of the antioxidant glutathione on antidepressant-induced cytotoxicity.rCMECs were pre-incubated with glutathione for 48 h, after which cells were treated for 24 h with antidepressant drugs at their 24 h MTT IC 50 concentrations or at 10 μM. A MTT assay for cell cytotoxicity was then performed. Histograms depict mean values ± SD. Significant changes from controls are marked with asterisks. For significance: ** for p < 0.01, and * for p < 0.05.
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U N C O R R E C T E D P R O O F E. Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx Table 1 Antidepressant cytotoxicity evaluated using MTT, AB, and ATP assays.Cell viability was determined across an antidepressant concentration range of 0.1-100 μM. IC 50 s were estimated using non-linear regression from the line of best fit data with 95% confidence intervals, as detailed in previous publications (Elmorsy et al., 2014 (Elmorsy et al., , 2016 Elmorsy and Smith, 2015 Footnote: ND = not determined.
